N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]- p -amino...

Details N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]- p -amino... N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]- p -amino...

2005-11-30

2008-10-14

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S262200, C548S263200, C548S263800, C514S383000

Reexamination Certificate

active

07435752

ABSTRACT:
A series of S-triazolyl α-mercaptoacetanilides having N-(α-mercaptoacetyl) p amino benzoic acid derivatives.are provided, where Q is CO2H, or a salt or ester thereof, or a C(O)N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.

REFERENCES:
patent: 5939462 (1999-08-01), Connell et al.
patent: 6197779 (2001-03-01), Andries et al.
patent: 6245817 (2001-06-01), Connell et al.
patent: 6414147 (2002-07-01), Currie et al.
patent: 2002/0026186 (2002-02-01), Woloszko et al.
patent: 2003/0027433 (2003-02-01), Faur et al.
patent: 2005/0054639 (2005-03-01), Simoneau
patent: 2006/0135556 (2006-06-01), Girardet et al.
patent: 1050531 (1979-03-01), None
patent: WO 00/27850 (2000-05-01), None
patent: WO 02/070470 (2002-09-01), None
patent: WO 03/016306 (2003-02-01), None
patent: WO 03/097047 (2003-11-01), None
patent: WO 2004/030611 (2004-04-01), None
patent: WO 2004/050643 (2004-06-01), None
patent: WO 2004/050643 (2004-06-01), None
patent: WO 2004/069812 (2004-08-01), None
patent: WO 2005/028479 (2005-03-01), None
patent: WO 2005/118575 (2005-12-01), None
Ainsworth, C. 1,2,4-Triazole. Org. Syn., Coll. 1973; vol. V: 1070. (4 pages).
Badger, et al. Azaindoles. III. The synthesis of pyrazolo[3,4-b]pyridines and pyrazolo-[3,4,-d]pyrimidines. Aust. J. Chem. 1965; 18(8): 1267-71.
Berge, et al. Pharmaceutical salts. J. Pharm. Sci. 1977; 66(1): 1-19.
Bontems, et al. Guanosine analogues: Synthesis of nucleosides of certain 3-substituted 6-aminopyrazolo [3,4-d ]pyrimidin-4(5H)-ones as potential immunotherapeutic agents. J. Med. Chem. 1990; 33(8): 2174-8.
Conner, et al. Characterization of the funtional properties if env genes from long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 1996; 70(8): 5306-11.
Harrington, et al. Direct detection of infectious HIV-1 in blood using a centrifugation-indicator cell assay. J. Virol. Methods. 2000; 88(1): 111-5.
Ibata, et al. Formation and reaction of oxazoles: Synthesis of N-substituted 2-(aminomethyl)oxazoles. Bull. Chem. Soc. Jpn. 1989; 62: 618-20.
Ibata, et al. The acid catalyzed decomposition of diazo compounds, I. Synthesis of oxazoles in the BF3 catalyzed reaction of diazo carbonyl compounds with nitriles. Bull. Chem. Soc. Jpn. 1979; 52: 3597-600.
Larsen, et al. Prodrug forms for the sulfonamide group. I: Evaluation of N-acyl derivatives, N-sulfonylamidines, N-sulfonylfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharm. 1987; 37(1-2): 87-95.
Lewis, et al. Pyrazolopyrimidine nucleosides. 13. Synthesis of the novel C-nucleoside 5-amino-3-(β-D-ribofuranosyl)pyrazolo[4,3,-d]pyrimidin-7-one, a guanosine analogue related to the nucleoside antibiotic formycin B. J. Am. Chem. Soc. 1988; 104: 1073-7.
Liu, et al. An improved synthesis of 9-deazaguanine. Synthetic Communications. 2002; 32(24): 3797-802. (edited by Klaus Kielich).
Lopes, et al. Acyloxymethyl as a drug protecting group. Part 6: N-acyloxymethyl- and N-[(aminocarbonyloxy)methyl]sulfonamides as prodrugs of agents containing a secondary sulfonamide group. Bioorg. Med. Chem. 2000; 8(4): 707-16.
Ludovici, et al. Evolution of anti-HIV candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 2001; 11(17): 2235-9.
Olesen, P. The use of bioisosteric groups in lead optimization. Current Opinion Drug Discovery & Development. 2001; 4: 471-78.
Patani, et al. Bioisosterism: A rational approach in drug design. Chem. Rev. 1996; 96(8): 3147-76.
Platt, et al. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998; 72(4): 2855-64.
Popik, et al. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J. Virol. 2002; 76(10): 4709-22.
Poste, et al. Lipid Vesicles as Carriers for Introducing Biologically Active materials into Cells. Methods Cell Biol. 1976;14: 33-71.
Roos, et al. LuSIV cells: A reporter cell line for the detection and quantitation of a single cycle of HIV and SIV replication Virology. 2000; 273(2): 307-15.
Scott, et al. A new route to the imidazole-2-thiones from 2-thiohydantoins. Implications in the study of ergothioneine. Biochem J. 1968; 109(2):209-15.
Seela, et al. Synthesis of 2′-deoxyribofuranosides of 8-aza-7-deazaguanine and related pyrazolo[3,4-d]pyrimidines. Helvitica Chimica Acta. 1986; 69(7): 1602-13.
Seela, et al. The high-anti conformation of 7-halogenated 8-aza-7-deaza-2′-deoxy-guanosines: A study of the influence of modified bases of the sugar structure of nucleosides. Helvitica Chimica Acta. 1999; 82(1): 105-24.
Taylor, et al. Synthesis of pyrazolo[3,4-d]pyrimidine analogues of the potent antitumor agent N-{4-[2-amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid (LY231514). Tetrahedron. 1992; 48(37): 8089-100.
Youssif, et al. A Facile One-pot Synthesis of Fused 2-Thiouracils: Dipyrimidinopyridine, Pyrazolopyrimidine and Pyridazinopyrimidines. Bull. Kor. Chem. Soc. 2003; 24: 1429-32.
Girardet, et al. U.S. Appl. No. 11/661,079, entitled “S-triazolyl alpha-mercaptoacetanildes as inhibitors of HIV reverse transcriptase,” filed Feb. 23, 2007.
De La Rosa et al., “Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase,” Bioorg Med Chem Lett 16:4444-4449, 2006.
Girardet et al., “The discovery of RDEA806, a potent new HIV NNRTI in phase 1 clinical trials,” poster at the 47thAnnual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, Sep. 17-20, 2007.
Hamatake et al., “RDEA806, a potent NNRTI with a high genetic barrier to resistance,” poster at the 47thAnnual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, Sep. 17-20, 2007.
Hamatake et al., “An IQ assessment of RDEA806, a potent NNRTI with an excellent activity profile in the presence of human serum proteins,” poster at the 15thConference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, Feb. 3-6, 2008.
Raney et al., “RDEA427 and RDEA640 are novel NNRTIs with potent anti-HIV activity against NNRTI-resistant viruses,” poster at the 15thConference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, Feb. 3-6, 2008.
Soliman et al., “Synthesis of some substituted mercaptotriazoles with possible anticonvulsant and monoamine oxidase inhibiting activities,” Bull Fac Pharm Cairo Univ 28(2):53-57, 1990.
Yeh et al., “RDEA806, a potent non-nucleoside reverse transcriptase inhibitor with less potential for drug-drug interactions,” poster at the 47thAnnual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, Sep. 17-20, 2007.
Yeh et al., “Safety and pharmacokinetics of ascending single oral doses of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in healthy volunteers,” poster at the 47thAnnual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, Sep. 17-20, 2007.

Affiliated with

Also associated with

Rating

N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]- p -amino... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]- p -amino..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]- p -amino... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4015479